https://www.selleckchem.com/pr....oducts/pkm2-inhibito
29; p = 0.019) and homeostatic model assessment for insulin resistance (HOMA-IR) significantly decreased in the vitamin K group (ES = -0.29; p = 0.019) compared to baseline, but their values were not significantly different compared to the placebo group at the end of the trial. No significant variation was observed in lipid profiles. Daily intake of 360µg Vitamin K in the form of MK-7 for 12-weeks reduces FPG and HbA1c in patients with T2DM but does not have a lipid-lowering effect. Daily intake of 360 µg Vitamin K2 i
Like
Comment
Share
